Drug Trial Radar · NCT05480761
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
312
Actual
Start
Aug 1, 2022
Primary completion
Sep 18, 2024
Study completion Sep 18, 2024
Sponsor
- Lead sponsor
- QOL Medical, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).
Conditions
- Congenital Sucrase-Isomaltase Deficiency
- CSID
- Sucrase Isomaltase Deficiency
Interventions
Sucraid (sacrosidase) Oral Solution 8500 IU/mLBiological
Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of Sucraid® treatment on gastrointestinal symptoms in subjects with low, moderate, and normal disaccharidase assay sucrase levels from an esophagogastroduodenoscopy (EGD).Time frame: Post 7-day run-in period plus 7-day treatment period.
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kidz Medical
Coral Gables, Florida
Orlando Health
Orlando, Florida
Children's Healthcare of Atlanta
Atlanta, Georgia
Center for Digestive Health Care, LLC
Atlanta, Georgia
University of Maryland Baltimore
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
GI Associates
Flowood, Mississippi
Happy Tummies
Flowood, Mississippi
Children's Mercy Hospital
Kansas City, Missouri
Atlantic Health System
Morristown, New Jersey
WNY Pediatric Gastroenterology
Buffalo, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Measurable Outcomes Research
Oklahoma City, Oklahoma
Prisma Health
Greenville, South Carolina
GI For Kids, PLLC
Knoxville, Tennessee
Newco 3A Research,LLC DBA 3A Research
El Paso, Texas
Pediatric GI of El Paso, LLC
El Paso, Texas
McGovern Medical School of UT Health
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.